Litcius/Paper detail

Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC

Ramalingam, Suresh S, Vansteenkiste, Johan, Planchard, David, Cho, Byoung Chul, Gray, Jhanelle E, Ohe, Yuichiro, Zhou, Caicun, Reungwetwattana, Thanyanan, Cheng, Ying, Chewaskulyong, Busyamas, Shah, Riyaz, Cobo, Manuel, Lee, Ki Hyeong, Cheema, Parneet, Tiseo, Marcello, John, Thomas, Lin, Meng-Chih, Imamura, Fumio, Kurata, Takayasu, Todd, Alexander, Hodge, Rachel, Saggese, Matilde, Rukazenkov, Yuri, Soria, Jean-Charles, FLAURA Investigators

2020Open MIND287 citations

Topics & Concepts

OsimertinibMedicineOverall survivalInternal medicineOncologySurvival analysisSurvival rateMEDLINEProgression-free survivalClinical trialLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways
Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC | Litcius